S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Phase

Division (Location)

Study ID

NCT#

Brief Description
S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.